A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Prif Awdur: | Karim, Azrin |
---|---|
Awduron Eraill: | Islam, Farzana |
Fformat: | Project report |
Iaith: | English |
Cyhoeddwyd: |
Brac University
2024
|
Pynciau: | |
Mynediad Ar-lein: | http://hdl.handle.net/10361/24372 |
Eitemau Tebyg
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
gan: Islam, Saidul
Cyhoeddwyd: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
gan: Ahmed, Nafisa
Cyhoeddwyd: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
gan: Meem, Manila
Cyhoeddwyd: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
gan: Hossain, Sadman Sanjid
Cyhoeddwyd: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
gan: Jahan, Nusrat
Cyhoeddwyd: (2024)